AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03732378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 capsule
Description: Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)
Study NCT00474526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus
Study NCT03405727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral dietary supplements
Description: Protein enriched diet
Study NCT02917174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Asthma Management System
Description: Patients in this group use a smartphone app in their asthma self-management.
Study NCT02917174 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: traditional Asthma Management System
Description: Patients in this group use a printed asthma diary in their asthma self-management.
Study NCT02631447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 450 mg p.o. od
Study NCT02631447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 45 mg p.o. bid
Study NCT00474526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine
Study NCT02631447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
Study NCT02631447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
Study NCT00621790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam
Description: fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
Study NCT00621790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00474526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV
Study NCT00157339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 12 months
Study NCT00157339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injected insulin
Description: patient specific dose, injected, before meals, 12 months.
Study NCT03818152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional strength assessment
Description: Functional strength exercises to assess strength in lower limbs.
Study NCT02785939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV (arm II closed to accrual 12/18/2015)
Study NCT02785939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00474526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V
Study NCT00474526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP
Study NCT01077453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT02785939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03292016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: APL-130277 sublingual thin film
Study NCT03292016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APO-go
Description: Subcutaneous APO-go
Study NCT01077453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01077453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04546217 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Treadmill training + transfer package (TT+TP)
Description: Participants will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. In combination with the gait training, participants will also receive a group of behavioral strategies (Transfer Package). Participants will sign the behavioral contract to achieve safety while engaging in activities, increase use of the paretic leg in daily activities, and increase coordination of both legs. A list of activities to be performed outside the clinical setting, the Home Skill Assignment, will be developed for each day of the week during the treatment period and given to the participants at the end of the session. The Home Practice after treatment aims to assure continued progress with LE use after the intervention program is completed. The LE-MAL Log will be administered in all sessions to assess quality of movement of the affected leg, level of assistance needed to perform daily activities, and level of confidence.
Study NCT04546217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training (TT)
Description: Participants in this group will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. The treadmill training will be identical to the experimental group, but no element of the TP will be delivered.
Study NCT02819167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neurologic and neuropsychological evaluation
Description: cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
Study NCT03788603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
Study NCT01788553 — intervention group
Intervention type: OTHER
Intervention: remission prevalence of generalized anxiety disorder
Study NCT02523859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Hypnotic drug used for anesthesia
Study NCT02523859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Benzodiazepine being developed for sedation and anesthesia.
Study NCT02880787 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rocuronium
Description: Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
Study NCT02880787 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neuromuscular monitoring with TOFScan® and TOF-Watch SX®
Description: Each monitor on one arm
Study NCT05266443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus containing cultured milk drink
Description: Each bottle of 125ml cultured milk drink contains a billion colony forming unit (CFU) Lactobacillus acidophillus (LA-5) and Lactobacillus paracasei (L. CASEI-01). Each patient will be given 2 bottles to consume daily for a period of 12 weeks.
Study NCT05266443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus containing cultured milk drink
Description: Each bottle of 125ml cultured milk drink contains a billion colony forming unit (CFU) Lactobacillus acidophillus (LA-5) and Lactobacillus paracasei (L. CASEI-01). Each patient will be given 2 bottles to consume daily for a period of 12 weeks.
Study NCT05266443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cultured milk drink
Description: The placebo prepared was identical to the probiotic-containing product in terms of color, taste and packaging. However, there is no trace of live microorganism in this product.
Study NCT01637805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene
Description: AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
Study NCT02297659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Fascial Closure
Description: Abdominal wall closure following damage control laparotomy.
Study NCT02297659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wound vac dressing application
Description: temporary abdominal wall closure with this device after damage control laparotomy
Study NCT02296502 — intervention group
Intervention type: OTHER
Intervention: DSM
Description: Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder
Study NCT03292016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apokyn
Description: Subcutaneous APOKYN
Study NCT01497353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position at introitus level
Description: After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
Study NCT01497353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: position at Maternal Abdomen
Description: After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
Study NCT01494636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345 (solution)
Description: 3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
Study NCT01494636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345 (nebulised)
Description: 25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
Study NCT00350350 — intervention group
Intervention type: DEVICE
Intervention: oxygenated oil
Description: oxygenated oil in spray versus product reference (artificial saliva) dosage : one to two spray 5 times a day
Study NCT00350350 — intervention group
Intervention type: DEVICE
Intervention: medical device. Spray containing essentially oxygenated oil
Description: protective oral spray containing :~* 94.4% of oxygenated oil~* Silicium dioxide~* aspartame artificial flavoring
Study NCT00433212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Deliver non-invasive respiratory support via ventilator with nCPAP device
Study NCT00433212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Deliver non-invasive respiratory support via ventilator with NIPPV device
Study NCT04252443 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of nurses' knowledge and attitudes about opioid analgesics working in a university hospital
Description: Interventions involving nurses' pharmacological level
Study NCT04660136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: contrast enhanced ultrasound
Description: We injected the second generation, ultrasonic contrast agent (SonoVue, Bracco, Milan, Italy) as a bolus of 0.03 ml/kg through a three-way 20-gauge catheter in an antecubital vein, followed by a bolus of 5 ml saline solution (0.9% NaCl).CEUS was performed with a 7.5MHz linear probe and contrast-tuned technology, based on allow mechanical index and a real-time scan to ensure the preservation of the contrast agent. A low acoustic power setting was used, expressing a low mechanical index (MI), 0.09-0.14, of a 7.5 MHz linear probe.
Study NCT00924690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Messages
Description: Participants will read 10 behavioral messages about colon cancer screening and physical activity.
Study NCT00924690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generic Messages
Description: Individuals will read 10 generic messages about colon cancer screening and physical activity.
Study NCT03232580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhAnnexin V-128
Description: All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
Study NCT02867215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barley bread
Description: 120g barley bread per day for 3 weeks.
Study NCT02867215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat bread
Description: 120g wheat bread per day for 3 weeks.
Study NCT04616872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate-LDE
Description: MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
Study NCT04616872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-LDE
Description: Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
Study NCT01302080 — intervention group
Intervention type: DRUG
Intervention: sertraline
Description: Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
Study NCT01302080 — intervention group
Intervention type: BEHAVIORAL
Intervention: psychotherapy
Description: Non-interventional study- as above
Study NCT01316406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH008
Description: The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
Study NCT01316406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATH008
Description: The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
Study NCT00814177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
Study NCT00814177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
Study NCT01494636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% sodium chloride solution)
Description: Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
Study NCT02016040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Focused Ultrasound
Study NCT03674359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BDG analysis
Description: BDG analysis
Study NCT01494636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
Study NCT04074265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Injection containing a mix of the above medications will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
Study NCT04074265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
Study NCT00603031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucagon like peptide -1
Description: continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
Study NCT00603031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: infusion with NaCl for 120 minutes as placebo-arm
Study NCT00603031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose dependent insulinotropic polypeptide
Description: continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
Study NCT03619473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard motorcycle child safety helmet
Description: Educational session followed by demonstration on~* proper helmet wearing~* how to differentiate non-standard and standard helmets~* how to keep motorcycle safe using ABCD concept~* importance of wearing bright clothes~* police summon for not wearing helmets~* live demo on poor performance of non-standard helmet~* giving away standard motorcycle child safety helmets~* oath taking by parents and children~* distribution and placement of VEM on parents' motorcycles
Study NCT01474486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronutrients
Description: Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
Study NCT04032132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin paste
Description: curcumin is a herb used for medical purpose
Study NCT04032132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curettage
Description: open flab debridement surgery
Study NCT04032132 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: curettage
Description: open flab debridement surgery
Study NCT04593043 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference
Study NCT04593043 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran dispensing claim is used as the exposure
Study NCT00621075 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Arterial Hypertension - Lung Perfusion Scans
Description: Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements
Study NCT04465500 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation
Description: EBRT will be administered every 5 consecutive days for 5 consecutive weeks. This is standard of care practice for this therapy. This may be revised as applicable per treating physician discretion. The dose of radiation will be in accordance with standard clinical practice guidelines for the treatment of prostate cancer.
Study NCT04465500 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: HDR Brachytherapy
Description: HDR brachytherapy will be administered per standard clinical practice (per NCCN guidelines version 1.2020 for prostate cancer), however standard clinical practice may vary between clinicians. Therefore, the dose of 15Gy in 1 fraction and a set of dosimetry guidelines are to be followed for the purposes of this study. A diagnostic MRI will be co-registered with Transrectal Ultrasound (TRUS) to perform the HDR brachytherapy.
Study NCT04465500 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Androgen Deprivation Therapy
Description: The dosing and administration of ADT will be in accordance with the drug label for the drug(s) used for this purpose. Participants may receive ADT before and/or during the course of this study.
Study NCT03189940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style modification by using and app with a wrist-worn activity tracker
Description: The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
Study NCT03189940 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Conventional Life style modification
Description: Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
Study NCT00601770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC41
Description: injection
Study NCT01282502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: 50 mg BID for 8 cycles
Study NCT03970655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1
Description: Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
Study NCT03970655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2
Description: Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
Study NCT00905385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHi Strain 2019
Description: Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
Study NCT01255163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-4 SC
Description: Exenatide 5 mcg or 10 mcg SC twice daily